H.C. Wainwright initiated coverage of Connect Biopharma with a Buy rating and $7 price target. The company is focused on developing next generation assets against validated targets in immunology and inflammatory diseases, the analyst tells investors in a research note. The analyst says the “highly positive” results for rademikibart in atopic dermatitis and asthma announced, an excluding China partnership or licensing deal in 2024 is likely, which would be a significant catalyst.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNTB: